147 results found.

Hepatitis C Clinical Trial using MK-5172

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172.
MK-5172

Hepatitis C Clinical Trial using AdCh3NSmut1; Placebo; MVA-NSmut

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 45 years.
- A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut.
AdCh3NSmut1; Placebo; MVA-NSmut

Chronic Hepatitis C, Hepatitis C Virus, or Compensated Cirrhosis Clinical Trial using ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

AbbVie - Recruiting 18 years to 70 years.
- A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

Hepatitis Clinical Trial using MK-5172

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients.
MK-5172

Hepatitis C Clinical Trial

Hologic, Inc. - Recruiting 18 years or older.
- Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay.

Hepatitis C, Chronic, or Infection Clinical Trial using TMC435; Pegylated interferon alfa-2a (PegIFNà-2a); Ribavirin (RBV)

Janssen-Cilag International NV - Recruiting 18 years to 70 years.
- A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Na‹ve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection.
TMC435; Pegylated interferon alfa-2a (PegIFNà-2a); Ribavirin (RBV)

Hepatitis B, Chronic, or Tumor Clinical Trial using TDF

Chang Gung Memorial Hospital - Recruiting 18 years to 70 years.
- Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy.
TDF

Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirr Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure.
IDN-6556

Chronic Hepatitis B Clinical Trial using Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Novartis - Recruiting 18 years or older.
- OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept.
Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Hepatocellular Carcinoma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis.
Nivolumab

Hepatitis B, Chronic Clinical Trial using PEG-IntronT; PEGASYST

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-IntronT Versus PEGASYST in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450).
PEG-IntronT; PEGASYST

Chronic Hepatitis B Clinical Trial using tenofovir; entecavir

Korea University - Recruiting 19 years or older.
- .
tenofovir; entecavir

Hepatitis C Clinical Trial using TT-034

Tacere Therapeutics, Inc. - Recruiting 18 years to 65 years.
- A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection.
TT-034

Hepatitis B Chronic Infection, or Pregnancy Clinical Trial using tenofovir disoproxil fumarate; placebo

Institut de Recherche pour le Developpement - Recruiting 18 years or older.
- Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization..
tenofovir disoproxil fumarate; placebo

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]

Hoffmann-La Roche - Recruiting 3 years to 17 years.
- A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B.
peginterferon alfa-2a [Pegasys]

De Novo Autoimmune Hepatitis Clinical Trial using Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Yale University - Recruiting 3 Months to 50 years.
- De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation.
Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Multicenter Observational Trial to Evaluate Correlation Between Liver Biopsy and Transient Elastography in Liver Fibrosis Assessment and Correlation Between Viral Kinetics and Transient Elastography Evolution During Hepatitis C Treatment in a Population of Chronic HCV Infected Patients.

Chronic Hepatitis C Clinical Trial using LDV/SOF FDC; SOF; RBV; PEG; GS-9669; GS-5816

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection.
LDV/SOF FDC; SOF; RBV; PEG; GS-9669; GS-5816

Hepatitis C Clinical Trial using MK-5172; MK-8742; Placebo; Ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ñ Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection.
MK-5172; MK-8742; Placebo; Ribavirin

Hepatitis, Chronic Clinical Trial

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts.

Hepatitis C, Chronic Clinical Trial using PEG-IFN alfa-2b; ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment).
PEG-IFN alfa-2b; ribavirin

Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Poliomyelitis, Clinical Trial using HexaximT: DTaP-IPV-Hep B-PRP~T combined vaccine

Sanofi - Recruiting 6 Weeks to 8 Weeks.
- Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth.
HexaximT: DTaP-IPV-Hep B-PRP~T combined vaccine

Hepatitis C, Chronic Clinical Trial using Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase III Randomised, Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection.
Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Hepatitis C Clinical Trial using BZF961; Ritonavir; Placebo

Novartis - Recruiting N/A or older.
- Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients.
BZF961; Ritonavir; Placebo

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial using Tenofovir/ & amp; Emtricitabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B.
Tenofovir/ & amp; Emtricitabine

Malaria Clinical Trial using Pfs25-EPA; Euvax/Hepatitis B vaccine; Menatra/Meningococcal Groups A, C, Y, W-135 vaccine; Alhydrogel

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali.
Pfs25-EPA; Euvax/Hepatitis B vaccine; Menatra/Meningococcal Groups A, C, Y, W-135 vaccine; Alhydrogel

Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area.

Hepatitis C, or Human Immunodeficiency Virus Clinical Trial using Boceprevir

Erasmus Medical Center - Recruiting 18 years or older.
- Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial..
Boceprevir

Hepatitis C Clinical Trial using TMC435

Janssen R&D Ireland - Recruiting 18 years or older.
- A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study..
TMC435

Hepatitis C Chronic Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- An Observational Post-Authorization Safety Study (PASS) of VictrelisT (Boceprevir) Among Chronic Hepatitis C Patients.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients.

Hepatocellular Carcinoma Clinical Trial using MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

SYZ Cell Therapy Co.. - Recruiting 20 years to 70 years.
- Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens.
MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Hepatitis A Clinical Trial using Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

GlaxoSmithKline - Recruiting 6 Months to 35 Months.
- An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children.
Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

Hepatitis C Clinical Trial using Peginterferon lambda

Nanogen Pharmaceutical Biotechnology Co., Ltd - Recruiting 18 years to 65 years.
- The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients.
Peginterferon lambda

Hepatitis B, Cirrhosis, or Awaiting Organ Transplant Clinical Trial using HBV vaccine

Fundaci¢n P£blica Andaluza para la gesti¢n de la Investigaci¢n en Sevilla - Recruiting 18 years to 65 years.
- Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation.
HBV vaccine

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C Clinical Trial using eltrombopag; placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients.
eltrombopag; placebo

Hepatitis C, Liver Disease Clinical Trial using DEB025 200mg; DEB025 300mg; DEB025 400mg

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na‹ve Patients.
DEB025 200mg; DEB025 300mg; DEB025 400mg

Alcoholic Hepatitis Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 21 years or older.
- A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy.
IDN-6556

Hepatitis C Clinical Trial using DCV/ASV/BMS-791325

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.
DCV/ASV/BMS-791325

Arthritis, Rheumatoid, Spondylarthritis, or Vasculitis Clinical Trial using Hepatitis A vaccine and tetanus vaccine

University of Zurich - Recruiting 18 years or older.
- A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls.
Hepatitis A vaccine and tetanus vaccine

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 4, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBE-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2A 40KD (PEG-IFN) +/- Nucleos(t)Ide Analogue.

Chronic Hepatitis C Infection Clinical Trial using JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens.
JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

Dengue Fever Clinical Trial using CLEC5A

Kaohsiung Medical University Chung-Ho Memorial Hospital - Recruiting N/A or older.
- Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection.
CLEC5A

Hepatitis C, Chronic Clinical Trial using Stop trial intervention for boceprevir, PEG-IFN and RBV

Kaohsiung Medical University Chung-Ho Memorial Hospital - Recruiting 20 years to 80 years.
- Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy.
Stop trial intervention for boceprevir, PEG-IFN and RBV

Hepatitis B Virus, or HIV Clinical Trial using Standard of care

University of North Carolina, Chapel Hill - Recruiting 18 years or older.
- CIDRZ-1220 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA).
Standard of care

Hepatitis C Virus Clinical Trial using 150 mg/daily chloroquine compare to placebo for 12 week; Chloroquine; placebo

Shiraz University of Medical Sciences - Recruiting 18 years to 60 years.
- .
150 mg/daily chloroquine compare to placebo for 12 week; Chloroquine; placebo

Hepatitis C Clinical Trial using TD-6450; Placebo

Theravance, Inc. - Recruiting 18 years to 60 years.
- A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects.
TD-6450; Placebo

Hepatitis C Infection, or Thrombocytopenia Clinical Trial using romiplostim; ribavirin; placebo; PEG-interferon alfa-2a; laboratory biomarker analysis

University of Southern California - Recruiting 18 years or older.
- A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia.
romiplostim; ribavirin; placebo; PEG-interferon alfa-2a; laboratory biomarker analysis

Hepatitis C, Chronic, or Human Immunodeficiency Virus Clinical Trial using DAA against HCV

Valme University Hospital - Recruiting 18 years or older.
- Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
DAA against HCV

Healthy Subjects, or Hepatitis B Clinical Trial using Hepatitis B Vaccine (Recombinant)

Rockefeller University - Recruiting 18 years to 60 years.
- Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers.
Hepatitis B Vaccine (Recombinant)

HIV, or Hepatitis B Clinical Trial using Tenofovir/lamivudine/lopinavir-ritonavir; Zidovudine/lamivudine/lopinavir-ritonavir

Centers for Disease Control and Prevention - Recruiting 20 years or older.
- Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers.
Tenofovir/lamivudine/lopinavir-ritonavir; Zidovudine/lamivudine/lopinavir-ritonavir

Hepatitis C Clinical Trial using MK-5172; MK-8742; Ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection.
MK-5172; MK-8742; Ribavirin

Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD Clinical Trial using Transient elastography, acoustic radiation force impulse, magnetic resonance elastography

Centre hospitalier de l'Universit‚ de Montr‚al (CHUM) - Recruiting 18 years or older.
- Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis.
Transient elastography, acoustic radiation force impulse, magnetic resonance elastography

Hepatitis C Virus Clinical Trial using Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Na‹ve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Hepatitis C Virus Clinical Trial using GS-5816

Gilead Sciences - Recruiting 18 years to 79 years.
- A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment.
GS-5816

HBsAg(+) Donor Kidney Allograft, or HBsAg(-) Donor Kidney Allogra Clinical Trial using HBsAg positive kidney allograft donor

Chulalongkorn University - Recruiting 18 years to 65 years.
- The Outcomes of Kidney Transplantation Between Recipients Receiving Graft From Donors With Positive and Negative HBsAg.
HBsAg positive kidney allograft donor

Hepatitis, Alcoholic Clinical Trial using Ademethionine; Polyene Phosphatidyl choline

Zhejiang Hisun Pharmaceutical Co. Ltd. - Recruiting 20 years to 65 years.
- Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis.
Ademethionine; Polyene Phosphatidyl choline

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYSr Plus COPEGUSr in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Observational Study on Predictors of On-treatment Response and Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegylated Interferons in Georgia.

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers.

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression.
peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Hepatitis C, Chronic Clinical Trial using peginterferon alfa-2a; ribavirin; boceprevir

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.
peginterferon alfa-2a; ribavirin; boceprevir

Hepatitis C Clinical Trial using ABT-450/ritonavir; ABT-333; ABT-267

AbbVie - Recruiting 18 years to 80 years.
- A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
ABT-450/ritonavir; ABT-333; ABT-267

Pregnancy, or HBV Clinical Trial using Tenofovir DF

Hopital LariboisiŠre - Recruiting 18 years or older.
- Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL.
Tenofovir DF

CHB Patients Without Significant Alcohol Consumption or Other Kno Clinical Trial

Seoul National University Boramae Hospital - Recruiting 20 years to 80 years.
- Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease.

Hepatitis C, Chronic Clinical Trial using VGX-6150

VGX International, Inc. - Recruiting 19 years to 65 years.
- Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection.
VGX-6150

HBV Infection Clinical Trial

Southwest Hospital, China - Recruiting 18 years to 65 years.
- The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication.

Insulin Resistance Clinical Trial

University of California, San Francisco - Recruiting 18 years to 60 years.
- Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos.

HCV Infection Clinical Trial using MK-8876 200 mg or ó800 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients.
MK-8876 200 mg or ó800 mg

Hepatitis C Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population.

Breast Cancer, Colon Cancer, or Bladder Cancer Clinical Trial using Glycosylated Recombinant Human Interleukin-7; Diphtheria-Tetanus Vaccine; Polio Vaccine; Pneumaococcal Vaccine; Hepatitis A Vaccine; Hepatitis B Vaccine; Influenza Vaccine; PhiX 174

National Institutes of Health Clinical Center (CC) - Recruiting 60 years or older.
- A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy.
Glycosylated Recombinant Human Interleukin-7; Diphtheria-Tetanus Vaccine; Polio Vaccine; Pneumaococcal Vaccine; Hepatitis A Vaccine; Hepatitis B Vaccine; Influenza Vaccine; PhiX 174

Cirrhosis, Chronic Hepatitis C, Hepatitis C, or Hepatitis C, Chro Clinical Trial using Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C.
Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

Biliary Liver Cirrhosis,, Hemochromatosis, Hepatitis, Hepatolenti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Evaluation of Patients With Liver Disease.

Hepatitis B Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Duration of Long-Term Immunity After Hepatitis B Virus Immunization.

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study).

Hepatitis C, Chronic Clinical Trial using Fixed Dose GS-7977/GS-5885; FDC with GS-9451; FDC with GS-9669

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients.
Fixed Dose GS-7977/GS-5885; FDC with GS-9451; FDC with GS-9669

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Withdrawal of Therapy After Long-Term Oral Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B.

Hepatitis C, or HIV Infections Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications.

Chronic Hepatitis C Virus, or Non Alcoholic Fatty Liver Disease Clinical Trial using normocaloric low cholesterol diet

University of Roma La Sapienza - Recruiting 40 years to 70 years.
- Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano.
normocaloric low cholesterol diet

Hepatitis, HIV, or Liver Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection.

Chronic Hepatitis C Clinical Trial using TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients.
TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Hepatitis C, Chronic Clinical Trial using Pegylated interferon alfa 2b; Ribavirin

Kirby Institute - Recruiting 18 years or older.
- A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use.
Pegylated interferon alfa 2b; Ribavirin

Hepatitis B Clinical Trial

National University Hospital, Singapore - Recruiting 21 years to 45 years.
- Antigen-specific Immune Response to Hepatitis B Virus and Influenza A (H1N1 Strain) in Utero.

Hepatitis, or Hepatitis C Clinical Trial using Algeron; Pegasys

Biocad - Recruiting 18 years to 70 years.
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C.
Algeron; Pegasys

Chronic Hepatitis C Clinical Trial using Sofosbuvir; RBV; PEG

Gilead Sciences - Recruiting 18 years or older.
- An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies.
Sofosbuvir; RBV; PEG

Hepatitis C, Chronic Clinical Trial using Simprenavir; Daclatasvir; Ribavarin

Janssen R&D Ireland - Recruiting 18 years or older.
- Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation.
Simprenavir; Daclatasvir; Ribavarin

Chronic Hepatitis B Clinical Trial using peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly; Nucleos(t)ide analogue therapy

National University Health System, Singapore - Recruiting 21 years to 65 years.
- SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL).
peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly; Nucleos(t)ide analogue therapy

Hepatitis C Clinical Trial using boceprevir; PegIFN-2b; RBV

Merck Sharp & Dohme Corp. - Recruiting 18 years to 75 years.
- A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00).
boceprevir; PegIFN-2b; RBV

Chronic Hepatitis C(CHC) Clinical Trial using MP-424; RBV; IFN beta

Mitsubishi Tanabe Pharma Corporation - Recruiting 20 years to 70 years.
- A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Na‹ve or Have Received Interferon Based Therapy.
MP-424; RBV; IFN beta

Acute Alcoholic Hepatitis Clinical Trial using ELAD treatment; Standard of care (Control)

Vital Therapies, Inc. - Recruiting 18 years or older.
- A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD).
ELAD treatment; Standard of care (Control)

HBV, or Chronic HBV Infections Clinical Trial using Tenofovir alafenamide; Tenofovir DF; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir DF; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

HBV, or Chronic HBV Infections Clinical Trial using Tenofovir alafenamide; Tenofovir disoproxil fumarate; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir disoproxil fumarate; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Hepatitis C Virus Clinical Trial using ABT-450/r/ABT-267 plus Ribavirin

AbbVie - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Na‹ve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
ABT-450/r/ABT-267 plus Ribavirin

Human Immunodeficiency Virus (HIV), or Hepatitis C, Chronic Clinical Trial

George Washington University - Recruiting 18 years or older.
- The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System..

HIV-1 Infection Clinical Trial using Placebos of GTU-multiHIV B and LIPO-5 vaccines; GTU-multHIV B vaccine and LIPO-5 vaccine

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years to 59 years.
- Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count ò 600/mm3.
Placebos of GTU-multiHIV B and LIPO-5 vaccines; GTU-multHIV B vaccine and LIPO-5 vaccine

Hepatitis C, Chronic Clinical Trial using Telaprevir and Sofosbuvir

University of Florida - Recruiting 18 years or older.
- Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1.
Telaprevir and Sofosbuvir

HIV Infection Clinical Trial using adherence reinforcement; Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years or older.
- Systematic 'Adherence Intervention' Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study..
adherence reinforcement; Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)

Hepatitis C Clinical Trial using Sofosbuvir; RBV; PEG

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection..
Sofosbuvir; RBV; PEG

Acute Hepatitis C Clinical Trial using Peginterferon alfa-2a; Ribavirin

Kirby Institute - Recruiting 16 years or older.
- Treatment of Recently Acquired Hepatitis C Virus Infection.
Peginterferon alfa-2a; Ribavirin

Early Chronic Hepatitis C Clinical Trial using TPV/PEG-IFN/RBV

Kirby Institute - Recruiting 18 years to 60 years.
- DAA Based Therapy for Recently Acquired Hepatitis C.
TPV/PEG-IFN/RBV

Chronic Hepatitis C Infection Clinical Trial using Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment na‹ve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV.
Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

Liver Fibrosis Clinical Trial

Yonsei University - Recruiting 19 years to 80 years.
- .

Hepatitis C With Hemophilia Clinical Trial using Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks); No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)

University of Cincinnati - Recruiting 18 years or older.
- Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir.
Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks); No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)

Hepatitis C, or Alcohol Use Disorders Clinical Trial using baclofen; placebo

Department of Veterans Affairs - Recruiting 18 years or older.
- Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV.
baclofen; placebo

Chronic HIV Infection, or HCV Coinfection Clinical Trial using Fosamprenavir

Fundacion SEIMC-GESIDA - Recruiting 18 years or older.
- Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
Fosamprenavir

HIV, or Hepatitis C Clinical Trial using Intravenous Silibinin (iSIL)

University of Zurich - Recruiting 18 years or older.
- A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS).
Intravenous Silibinin (iSIL)

HIV Infections, or Hepatitis Clinical Trial

Virginia Commonwealth University - Recruiting 18 years to 90 years.
- HIV-HCV Coinfection: Impact of Immune Dysfunction.

Hepatitis C, or Infection Transmission, Maternal-Fetal Clinical Trial

University of North Carolina, Chapel Hill - Recruiting N/A or older.
- The Pathogenesis of Hepatitis C Virus Vertical Transmission.

HBeAg-Positive Chronic Hepatitis B Clinical Trial using Baracle Tab.r; Baraclude Tab.r

Dong-A Pharmaceutical Co., Ltd. - Recruiting 18 years to 65 years.
- A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.r and Baraclude Tab.r for HBeAG Chronic Hepatitis B.
Baracle Tab.r; Baraclude Tab.r

HIV-2 Infection Clinical Trial using emtricitabine / tenofovir disoproxil fumarate / raltegravir .

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years or older.
- ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients.
emtricitabine / tenofovir disoproxil fumarate / raltegravir .

Hepatitis C Clinical Trial using Pegylated Interferon Lambda; Ribasphere; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years to 70 years.
- A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment na‹ve Subjects.
Pegylated Interferon Lambda; Ribasphere; Daclatasvir

HIV, Tuberculosis, or Pediatric Clinical Trial using Development of a diagnosis algorithm

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting N/A to 13 years.
- Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research).
Development of a diagnosis algorithm

Chronic Hepatitis C Clinical Trial

Beijing 302 Hospital - Recruiting 1 year to 18 years.
- Pharmacogenomics Study on IL28B Genetic Variants for Prediction of Drug Response in Chinese Children With HCV Infection..

Hepatitis B, or Renal Failure With Tubular Necrosis Clinical Trial using plasma and urine samples, sample with ADN

University Hospital, Limoges - Recruiting 18 years or older.
- Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus..
plasma and urine samples, sample with ADN

HIV, Herpes Simplex 2, Hepatitis C, Hepatitis B, or Chagas Diseas Clinical Trial using HIV Counseling and Testing; Blood Donation

Blood Systems Research Institute - Recruiting 18 years to 65 years.
- Improving Blood Safety and HIV Testing in Brazil: a Randomized Controlled Trial.
HIV Counseling and Testing; Blood Donation

Hepatitis C Clinical Trial using Pegylated interferon alpha; Ribavirin

Fremantle Hospital and Health Service - Recruiting 18 years to 70 years.
- Is Hepcidin a Possible Contributor to Impaired Iron Mobilization and Anaemia in Hepatitis C Patients Treated With Pegylated Interferon Alpha and Ribavirin Therapy? A Pilot Study.
Pegylated interferon alpha; Ribavirin

Chronic Hepatitis C Clinical Trial using Pegylated interferon alfa-2a + ribavirin

National Taiwan University Hospital - Recruiting 18 years or older.
- Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response.
Pegylated interferon alfa-2a + ribavirin

Hepatitis B Clinical Trial using Entecavir prophylaxis; Therapeutic entecavir

Peking University - Recruiting 18 years or older.
- Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma.
Entecavir prophylaxis; Therapeutic entecavir

Chronic Hepatitis C, Chronic Hepatitis B, Biopsy, or Hemodialysis Clinical Trial using Percutaneous liver biopsy

National Taiwan University Hospital - Recruiting N/A or older.
- Safety Profiles of Percutaneous Liver Biopsy in Hemodialysis Patients With Chronic Hepatitis C Pre-treated With 1-Deamino-8- D-Arginine Vasopressin.
Percutaneous liver biopsy

Hepatitis B, Chronic Clinical Trial using Entecavir and peginterferon alfa-2a; Placebo and peginterferon

National Taiwan University Hospital - Recruiting 18 years or older.
- Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B.
Entecavir and peginterferon alfa-2a; Placebo and peginterferon

Hepatitis C Clinical Trial using rimantadine

The Leeds Teaching Hospitals NHS Trust - Recruiting 18 years to 65 years.
- A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin.
rimantadine

Chronic Hepatitis C Clinical Trial using ChronVac-C + SOC; SOC

ChronTech Pharma AB - Recruiting 18 years to 65 years.
- A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Na‹ve Subjects.
ChronVac-C + SOC; SOC

Chronic Hepatitis C Clinical Trial using Quercetin

University of California, Los Angeles - Recruiting 18 years to 65 years.
- A Phase 1 Study of Quercetin in Patients With Hepatitis C.
Quercetin

HIV Infections, or Hepatitis C Clinical Trial using Raltegravir; Atazanavir/Ritonavir

St. James's Hospital, Ireland - Recruiting 18 years or older.
- An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-na‹ve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone.
Raltegravir; Atazanavir/Ritonavir

Chronic Hepatitis B Clinical Trial using Tenofovir; Telbivudine; Tenofovir plus Telbivudine

Institute of Liver and Biliary Sciences, India - Recruiting 18 years to 65 years.
- An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients.
Tenofovir; Telbivudine; Tenofovir plus Telbivudine

Hepatitis C Clinical Trial using Ribavrin; Abacavir plus Ribavirin

Johns Hopkins University - Recruiting 18 years to 55 years.
- Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment.
Ribavrin; Abacavir plus Ribavirin

Hepatitis C, Chronic, or HIV Infection Clinical Trial using Adherence questionnaire

Fundacion IMIM - Recruiting 18 years or older.
- Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C.
Adherence questionnaire

Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B, or Hepati Clinical Trial using CE-US (SonazoidT); B-mode US

Japan Liver Oncology Group - Recruiting 20 years or older.
- Sonazoid Enhanced Liver Cancer Trial for Early Detection.
CE-US (SonazoidT); B-mode US

Normal, Alcoholism, Cirrhosis, or Hepatitis C Clinical Trial using Ultrasound

Temple University - Recruiting 20 years to 70 years.
- Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound..
Ultrasound

HIV, or Hepatitis C Clinical Trial using Motivational interviewing; Educational intervention

Universit‚ de Sherbrooke - Recruiting 16 years or older.
- Effects of a Brief Motivational Intervention on Risky Injection Practices Among Injecting Drug Users.
Motivational interviewing; Educational intervention

Hepatitis B Clinical Trial using Educational Small Group Session; Educational small group session

University of California, Los Angeles - Recruiting 18 years to 64 years.
- Increasing Hepatitis B Screening Among Korean Church Attendees (Component Project) Program Project Title: Liver Cancer Control Interventions for Asian Americans.
Educational Small Group Session; Educational small group session

Liver Cirrhosis Clinical Trial

National Taiwan University Hospital - Recruiting 50 years to 70 years.
- Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).

Chronic HCV Infection, or Nonalcoholic Steatohepatitis Clinical Trial using pegylated interferon; Ribavarin

Charles University, Czech Republic - Recruiting 18 years to 60 years.
- Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection.
pegylated interferon; Ribavarin

Hepatocellular Carcinoma, Hepatitis B, or Hepatitis C Clinical Trial

National Taiwan University Hospital - Recruiting N/A or older.
- Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by Surface-Enhanced Laser Desorption/Ionization (SELDI).

Hepatitis B Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 90 years.
- Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative, Have Normal ALT, and HBV DNA ò10,000 Copies/mL.

Hepatitis C, Hepatitis B, Autoimmune Hepatitis, Liver Cirrhosis, Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.

Hepatitis C, or Hepatitis B Clinical Trial using Pegasys; Copegus.

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Anti-Viral Therapy.
Pegasys; Copegus.

Hepatitis C, or Hepatitis B Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 65 years.
- An Investigation of Cognitive Functioning and Brain Metabolites in Patients With Non-Cirrhotic Hepatitis-C Both Pre- and Post-Treatment With Antiviral Medication.